Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.
Ruiz A, Pesini P, Espinosa A, Pérez-Grijalba V, Valero S, Sotolongo-Grau O, Alegret M, Monleón I, Lafuente A, Buendía M, Ibarria M, Ruiz S, Hernández I, San José I, Tárraga L, Boada M, Sarasa M. Ruiz A, et al. PLoS One. 2013 Nov 27;8(11):e81334. doi: 10.1371/journal.pone.0081334. eCollection 2013. PLoS One. 2013. PMID: 24312290 Free PMC article.
Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A, Alegret M, Pesini P, Valero S, Lafuente A, Buendía M, San José I, Ibarria M, Tejero MA, Giménez J, Ruiz S, Hernández I, Pujadas F, Martínez-Lage P, Munuera J, Arbizu J, Tárraga L, Hendrix SB, Ruiz A, Becker JT, Landau SM, Sotolongo-Grau O, Sarasa M, Boada M; AB255 Study Group; Alzheimer’s Disease Neuroimaging Initiative. Espinosa A, et al. Among authors: san jose i. J Alzheimers Dis. 2017;57(2):447-459. doi: 10.3233/JAD-161223. J Alzheimers Dis. 2017. PMID: 28269787 Free PMC article.
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial.
Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, Sarasa L, Canudas J, Badi H, Monleón I, San-José I, Munuera J, Rodríguez-Gómez O, Abdelnour C, Lafuente A, Buendía M, Boada M, Tárraga L, Ruiz A, Sarasa M. Lacosta AM, et al. Among authors: san jose i. Alzheimers Res Ther. 2018 Jan 29;10(1):12. doi: 10.1186/s13195-018-0340-8. Alzheimers Res Ther. 2018. PMID: 29378651 Free PMC article. Clinical Trial.
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
Pérez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, Guillen F, Monleón I, San-José I, Martínez-Lage P, Munuera J, Hernández I, Buendía M, Sotolongo-Grau O, Alegret M, Ruiz A, Tárraga L, Boada M, Sarasa M; AB255 Study Group. Pérez-Grijalba V, et al. Among authors: san jose i. Alzheimers Res Ther. 2019 Dec 1;11(1):96. doi: 10.1186/s13195-019-0549-1. Alzheimers Res Ther. 2019. PMID: 31787105 Free PMC article.
33 results